药理学
缺血
氯化四氮唑
星形胶质细胞
线粒体
中枢神经系统
再灌注损伤
生物
医学
麻醉
化学
生物化学
内分泌学
内科学
作者
Shusheng Ge,Liwei Zhang,Xiaoqian Cui,Yuan Li
出处
期刊:Neuroscience
[Elsevier]
日期:2022-08-01
卷期号:498: 203-213
被引量:2
标识
DOI:10.1016/j.neuroscience.2022.07.005
摘要
Cerebral ischemia/reperfusion injury (CIRI) is closely related to mitochondrial dysfunction in astrocytes. Therefore, based on glucose transporter 1 (GLUT1), which is highly expressed in the brain tissue of rats with CIRI, we design a kind of brain-targeted dexmedetomidine (Man@Dex) nanomicelles. The results showed that Man@Dex not only had the advantages of small particle size, stability and non-toxicity, but also realized brain-targeted drug delivery. Primary astrocytes were cultured in vitro to construct CIRI cell model. It was found that Man@Dex could improve the activity of injured astrocytes. Man@Dex could exert antioxidant activity by inhibiting the reactive oxygen species (ROS) production of astrocytes, thus inhibiting the cytotoxicity induced by hypoxia and reoxygenation. Man@Dex could improve the ATP level and mitochondrial membrane potential (MMP) to protect mitochondrial function of damaged astrocytes. The CIRI rat model was constructed and confirmed by hematoxylin and eosin (HE), Triphenyl-2H-tetrazolium chloride (TTC) staining and nerve defect score. It indicated that Man@Dex could alleviate CIRI and improve MMP, which was beneficial to the recovery of brain injury in rats. This research provides a new theoretical basis and target for the development of brain-targeted nano-drugs of CIRI.
科研通智能强力驱动
Strongly Powered by AbleSci AI